Monthly Prescribing Reference

Label Mix-Up Prompts Recall of IV Amiodarone, Tranexamic Acid

Inadvertent administration may result in serious adverse events. Mylan announced the voluntary recall to the hospital/clinic level of 4 lots of Amiodarone HCl Injection, USP 450mg/9mL and Tranexamic ...
Nasdaq

Mylan Recalls Certain Lots Of Amiodarone HCl, Tranexamic Acid Injections

(RTTNews) - Generic and specialty pharma company Mylan N.V. said its U.S.-based business Mylan Institutional LLC recalled four lots of Amiodarone HCl Injection, USP and Tranexamic Acid Injection, USP ...
Yahoo Finance

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic ...

Study results expected to form the basis of a supplemental New Drug Application (sNDA) planned for submission in Q2 2026 WOBURN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: ...
Seeking Alpha

Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026 Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansion More ...
Nasdaq

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic ...

WOBURN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...